{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:48:37Z","timestamp":1790135317304,"version":"4.0.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Precision medicine based on biomarkers, such as genetic abnormalities and PD-L1 expression, has been established for the treatment of nonsmall cell lung cancer. Recently, liquid biopsy has emerged as a valuable and minimally invasive alternative. This method analyzes blood and other bodily fluids to detect cancer-related genetic abnormalities and molecular residual disease (MRD). Liquid biopsy, which includes testing for circulating tumor cells, circulating tumor DNA (ctDNA), and microRNA (miRNA), offers several advantages over conventional methods. It is minimally invasive, can be performed repeatedly, and provides crucial information for early cancer diagnosis, genotyping, and treatment monitoring. Elevated ctDNA levels and miRNA markers show promise for early diagnosis. Liquid biopsy complements traditional tissue biopsy during genotyping, particularly when tumor samples are insufficient. Tests such as Cobas\u00ae EGFR Mutation Test v2 and Guardant360\u00ae CDx have been shown to be effective in detecting genetic mutations and guiding treatment decisions. Although the accuracy of liquid biopsy is still lower than that of tissue biopsy, its clinical utility continues to improve. For cancer prediction recurrence and treatment monitoring, ctDNA analysis can detect MRD earlier than conventional imaging, offering potential benefits for treatment adjustment and early relapse detection. The continuous development and validation of liquid biopsy methods are essential for improving personalized lung cancer treatment strategies.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf013","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:56:06Z","timestamp":1742374566000},"page":"453-458","source":"Crossref","is-referenced-by-count":5,"title":["Liquid biopsy in lung cancer"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0828-5025","authenticated-orcid":false,"given":"Shingo","family":"Kitagawa","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"2025042804261374900_ref1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4065\/83.3.355","article-title":"Small cell lung cancer","volume":"83","author":"Sher","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2025042804261374900_ref2","doi-asserted-by":"publisher","first-page":"209ra153","DOI":"10.1126\/scitranslmed.3006802","article-title":"A genomics-based classification of human lung tumors","volume":"5","author":"Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM)","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025042804261374900_ref3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025042804261374900_ref4","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"2025042804261374900_ref5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2025042804261374900_ref6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13046-024-03026-7","article-title":"Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation","volume":"43","author":"Ren","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"2025042804261374900_ref7","doi-asserted-by":"publisher","first-page":"e2300647","DOI":"10.1200\/PO.23.00647","article-title":"Genomic landscape of circulating tumor DNA in patients with hormone receptor-positive\/human epidermal growth factor Receptor-2-negative metastatic breast cancer treated with Abemaciclib: data from the SCRUM-Japan cancer genome screening project","volume":"8","author":"Hattori","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2025042804261374900_ref8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"key":"2025042804261374900_ref9","doi-asserted-by":"publisher","first-page":"e50176","DOI":"10.7759\/cureus.50176","article-title":"Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine","volume":"15","author":"Adhit","year":"2023","journal-title":"Cureus"},{"key":"2025042804261374900_ref10","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3390\/cells12222590","article-title":"Circulating tumor cells as predictive and prognostic biomarkers in solid tumors","volume":"12","author":"Capuozzo","year":"2023","journal-title":"Cells"},{"key":"2025042804261374900_ref11","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025042804261374900_ref12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","article-title":"Clinical relevance of circulating cell-free microRNAs in cancer","volume":"11","author":"Schwarzenbach","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2025042804261374900_ref13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41416-022-01777-8","article-title":"Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?","volume":"127","author":"Bonanno","year":"2022","journal-title":"Br J Cancer"},{"key":"2025042804261374900_ref14","doi-asserted-by":"publisher","first-page":"639233","DOI":"10.3389\/fcell.2021.639233","article-title":"Cell-free DNA: hope and potential application in cancer","volume":"9","author":"Yan","year":"2021","journal-title":"Front cell Dev Biol"},{"key":"2025042804261374900_ref15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1749-6632.2000.tb06608.x","article-title":"The origin and mechanism of circulating DNA","volume":"906","author":"Stroun","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"2025042804261374900_ref16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/medsci11010008","article-title":"Different liquid biopsies for the management of non-small cell lung cancer in the mutational oncology era","volume":"11","author":"Palmieri","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"2025042804261374900_ref17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2025042804261374900_ref18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cllc.2023.01.006","article-title":"Liquid biopsy screening for early detection of lung cancer: current state and future directions","volume":"24","author":"Zhu","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2025042804261374900_ref19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.21037\/tlcr-22-712","article-title":"Significance of circulating tumor cells in lung cancer: a narrative review","volume":"12","author":"Hamilton","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2025042804261374900_ref20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bbcan.2014.10.001","article-title":"Liquid biopsies in lung cancer: the new ambrosia of researchers","volume":"1846","author":"Rolfo","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"2025042804261374900_ref21","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.21037\/tlcr-20-189","article-title":"Future perspectives from lung cancer pre-clinical models: new treatments are coming?","volume":"9","author":"Bersani","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2025042804261374900_ref22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.21037\/atm-23-1572","article-title":"Circulating tumour DNA analysis for early detection of lung cancer: a systematic review","volume":"12","author":"Lam","year":"2024","journal-title":"Ann Transl Med"},{"key":"2025042804261374900_ref23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"The TRACERx consortium","year":"2017","journal-title":"Nature"},{"key":"2025042804261374900_ref24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"2025042804261374900_ref25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fimmu.2017.00118","article-title":"Circulating microRNAs as potential biomarkers of infectious disease","volume":"8","author":"Correia","year":"2017","journal-title":"Front Immunol"},{"key":"2025042804261374900_ref26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12935-023-03133-z","article-title":"Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review","volume":"23","author":"Sadeghi","year":"2023","journal-title":"Cancer Cell Int"},{"key":"2025042804261374900_ref27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3892\/or.2022.8445","article-title":"MicroRNAs as early diagnostic biomarkers for non-small cell lung cancer (review)","volume":"49","author":"Liang","year":"2023","journal-title":"Oncol Rep"},{"key":"2025042804261374900_ref28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.lungcan.2014.01.013","article-title":"Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer","volume":"84","author":"VanderLaan","year":"2014","journal-title":"Lung Cancer"},{"key":"2025042804261374900_ref29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.21037\/atm.2017.01.32","article-title":"The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?","volume":"5","author":"Kwapisz","year":"2017","journal-title":"Ann Transl Med"},{"key":"2025042804261374900_ref30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib As first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025042804261374900_ref31","doi-asserted-by":"publisher","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-19-1126","article-title":"Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025042804261374900_ref32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025042804261374900_ref33","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025042804261374900_ref34","doi-asserted-by":"publisher","first-page":"107359","DOI":"10.1016\/j.lungcan.2023.107359","article-title":"Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: a real-world experience","volume":"185","author":"Porta","year":"2023","journal-title":"Lung Cancer"},{"key":"2025042804261374900_ref35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","article-title":"Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types","volume":"7","author":"Shu","year":"2017","journal-title":"Sci Rep"},{"key":"2025042804261374900_ref36","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med"},{"key":"2025042804261374900_ref37","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: A prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025042804261374900_ref38","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"key":"2025042804261374900_ref39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"2025042804261374900_ref40","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1158\/1078-0432.CCR-19-1213","article-title":"Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC)","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025042804261374900_ref41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/1878-0261.13116","article-title":"Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer","volume":"16","author":"Waldeck","year":"2022","journal-title":"Mol Oncol"},{"key":"2025042804261374900_ref42","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/cncr.33985","article-title":"Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer","volume":"128","author":"Li","year":"2022","journal-title":"Cancer"},{"key":"2025042804261374900_ref43","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nature Cancer"},{"key":"2025042804261374900_ref44","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1038\/s41467-024-51316-7","article-title":"Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy","volume":"15","author":"Ding","year":"2024","journal-title":"Nat Commun"},{"key":"2025042804261374900_ref45","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"2025042804261374900_ref46","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1200\/JCO.2024.42.16_suppl.8005","article-title":"Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB\u2013IIIA non-small cell lung cancer (NSCLC)","volume":"42","author":"John","year":"2024","journal-title":"JCO"},{"key":"2025042804261374900_ref47","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann Oncol"},{"key":"2025042804261374900_ref48","doi-asserted-by":"publisher","author":"Wakelee","DOI":"10.1016\/j.annonc.2024.08.1270"},{"key":"2025042804261374900_ref49","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2365","article-title":"Follow-up and surveillance of the patient with lung cancer after curative-intent therapy","volume":"143","author":"Colt","year":"2013","journal-title":"Chest"},{"key":"2025042804261374900_ref50","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"2025042804261374900_ref51","year":"2019"},{"key":"2025042804261374900_ref52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-022-01509-9","article-title":"Exosomes as a new frontier of cancer liquid biopsy","volume":"21","author":"Yu","year":"2022","journal-title":"Mol Cancer"},{"key":"2025042804261374900_ref53","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2025042804261374900_ref54","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00432-022-04034-w","article-title":"Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach","volume":"149","author":"Englmeier","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025042804261374900_ref55","doi-asserted-by":"publisher","first-page":"107794","DOI":"10.1016\/j.lungcan.2024.107794","article-title":"The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/5\/453\/62451092\/hyaf013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/5\/453\/62451092\/hyaf013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:26:21Z","timestamp":1745828781000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/5\/453\/8086521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,19]]},"published-print":{"date-parts":[[2025,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf013","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,19]]}}}